Core Insights - The company Shijiazhuang Pharmaceutical Group (石四药集团) has received approval from the National Medical Products Administration of China for three active pharmaceutical ingredients (APIs): Fenofibrate, Fenofibric Acid, and Sodium Phosphate of Levofloxacin [1] - Among these, Sodium Phosphate of Levofloxacin is the third API approved for use in China by domestic companies [1] Group 1: Product Approvals - Fenofibrate and Fenofibric Acid are primarily used for treating hyperlipidemia and hypercholesterolemia, as well as for lowering triglyceride levels in patients with severe hypertriglyceridemia [1] - Sodium Phosphate of Levofloxacin is mainly used for treating severe amoebic infections of the intestine and liver, infections caused by anaerobic bacteria sensitive to Metronidazole post-surgery, and for preventing infections from anaerobic bacteria during surgical procedures [1]

Core Viewpoint - The announcement from the company indicates that three active pharmaceutical ingredients (APIs) have been approved by the National Medical Products Administration of China for use in marketed formulations, highlighting the company's growth in the pharmaceutical sector [1] Group 1: Product Approvals - The three APIs approved are Fenofibrate, Fenofibric Acid, and Sodium Phosphate of Levofloxacin, with the latter being the third domestic company to receive approval [1] - Fenofibrate and Fenofibric Acid are primarily used for treating hyperlipidemia and hypercholesterolemia, as well as lowering triglyceride levels in patients with severe hypertriglyceridemia [1] - Sodium Phosphate of Levofloxacin is used for treating severe amoebic infections of the intestine and liver, as well as for preventing infections caused by anaerobic bacteria during surgical procedures [1]

Core Viewpoint - The announcement highlights that the company Shijiazhuang Pharmaceutical Group has received approval from the National Medical Products Administration of China for three active pharmaceutical ingredients, indicating a significant milestone in expanding its product offerings in the market [1] Group 1: Product Approvals - The three approved active pharmaceutical ingredients are Fenofibrate, Fenofibric Acid, and Sodium Phosphate of Levofloxacin, with the latter being the third domestic company to receive such approval [1] - Fenofibrate and Fenofibric Acid are primarily used for treating hyperlipidemia and hypercholesterolemia, as well as lowering triglyceride levels in patients with severe hypertriglyceridemia [1] - Sodium Phosphate of Levofloxacin is mainly used for treating severe amoebic infections of the intestines and liver, as well as for preventing infections caused by anaerobic bacteria during surgical procedures [1]